Application of metabonomics in drug development

Pharmacogenomics

Volumn 8, Issue 7, 2007, Pages 731-741

  Keun, Hector C ^a   Athersuch, Toby J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Drug development; Metabolic profiling; Metabolomics; Metabonomics; Personalized healthcare; Pharmacology; Toxicology; Translational research

Indexed keywords

BIOLOGICAL MARKER; PARACETAMOL; TRIMETHYLAMINE;

ANALYTIC METHOD; CAPILLARY ELECTROPHORESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS SPECTROMETRY; MEDICAL RESEARCH; METABOLITE; METABOLOMICS; NEPHROTOXICITY; NON INVASIVE MEASUREMENT; NONHUMAN; REVIEW; TOXICOLOGY;

DRUG THERAPY; GENE EXPRESSION PROFILING; HUMANS; METABOLISM; PHARMACEUTICAL PREPARATIONS; SAFETY;

EID: 34548065407     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.7.731     Document Type: Review

References (50)

1. Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': understanding the metabolic reponses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29(11), 1181-1189 (1999).
2. Fiehn O: Metabolomics - the link between genotypes and phenotypes. Plant Mol. Bid. 48, 155-171 (2002).
3. Raamsdonk LM, Teusink B, Broadhurst D et al.: A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotech. 19(1), 45-50 (2001).
4. 1H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue. Anal. Biochem. 293(1), 16-21 (2001).
5. Robertson DG: Matabonomics in toxicology: a review. Toxicol. Sci. 85(2), 809-822 (2DO5).
6. Keun HC: Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109(1-2), 92-106 (2006).
7. 1H-NMR-based metabonomics, Nat. Med. 8(12), 1439-1444(20O3).
8. Forgue P, Halouska S, Werth M, Xu K, Harris S, Powers R: NMR metabolic profiling of Aspergillusnidulans to monitor drug and protein activity. J. Proteome Res 5(8), 1916-1923 (2006).
9. Glunde K, Ackerstaff E, Mori N et al.: Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions Mol. Pharmaceutics 3(5), 496-506 (2006).
10. Glunde K, Serkova NJ: Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7(7), 1109-1123 (2006).
11. Griffin JL, Kauppinen RA: Tumour metabolomics in animal models of human cancer. J. Proteome Res 6(2), 498-505 (2007).
12. 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn. Reson. Med. 48(5) 819-825 (2002).
13. 31P-NMR study using a phosphonium analog of choline. Cancer Lett. 140(1-2), 189-194 (1999).
14. Al-Saffar NMS, Troy H, Ramírez de Molina A et al.: Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models Cancer Res 66(1), 427-434 (2006).
15. Espina JR, Shockcor JP, Herron WJ et al.: Detection of in vivo biomarkers of phosspholipidosis using NMR-based metabonomic approacheas Magn. Reson. Chem. 39(9), 559-565 (2001).
16. 1H NMR and magic angle spinning NMR spectroscopic investigation of the biochemical effects of 2-bromoethanamine in intact renal and hepatic tissue. Magn. Reson. Med. 45(5), 781-790 (2001).
17. Holmes E, Bonner FW, Sweetmen BC et al.: Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions the rat induced by mercury(II) chloride and 2-bromosthanamine Mol. Pharmacol. 42(5), 922-930 (1992).
18. Beckwith-Hall BM, Nicholson JK, Nicholls AW et al.: Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Toxicol. 11(4), 260-272 (1998).
19. Lindon JC, Keun HC, Ebbels TMD et al.: The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6(7), 691-699 (2005).
20. Sinha G:Trying to catch troublemakers with a metabolic profile. Science 310(5750), 965-966 (2005).
21. Dieterle F, Schlotterbeck G, Ross A, Niederhauser U, Sann H: Application of metabonomics a compound ranking study in early drug development revealing drug-induced excretion of choline into urine. Chem. Res Toxicol. 19(9), 1175-1181 (2006).
22. Soga T, Baran R, Suematsu M et al.: Differential metabolonomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 281(24), 16768-16776 (2006).
23. Clayton TA, Lindon JC, Cloarec O et al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006).
24. Holmes E, Tsang TM, Huang JT et al.: Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome schizophrenia PLoS Med. 3(8), 1420-1428 (2006).
25. Dumas ME, Barton RH, Toye A et al.: Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl Acad. Sci. USA 103(33), 12511-12516 (2006).
26. Stella C, Beckwith-Hall B, Cloarec O et al.: Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res 5(10), 2780-2788 (2006).
27. Robosky LC, Wells DF Egnash LA et al.: Metabonomic identification of two distinct phenotypes in in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci. 87(1), 277-284 (2005).
28. Nicholson JK, Wilson ID: Understanding 'global' systembiology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2(8), 668-676 (2003).
29. Plumb RS, Granger JH, Stumpf CL et al.: A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gander and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst 130(6), 884-849 (2005).
30. Ullsten S, Danielsson R, Bäckström D, Sjöberg P, Bergquist J. Urine profiling using capillary electrophoresis-mass spectrometry and multivariate data analysis. J. Chromatogr. A 1117(1), 87-93 (2006).
31. Casado B, Zanone C, Annovazzi L, Iadarola P, Whalen G, Baraniuk JN: Urinary electrophoretic profiles from chronic fatigue syndrome and chronic fatigue syndrome/fibromyalgia patients a pilot study for achieving their normalization. J. Chromatogr. B Analyst Technol. Biomed. Life Sci. 814(1), 43-51 (2005).
32. Szymañska E, Markuszewski MJ, Capron X et al.: Increasing conclusiveness of metabonomic studies by cheminformatic preprocessing of capillary electrophoretic data on urinary nucleoside profiles. J. Pharm. Biomed. Anal. 43(2), 413-420 (2007).
33. Ellis DI, Goodacre R: Metabolic fingerprinting in disease diagnosis biomedical applications of infrared and Raman spectroscopy. Analyst 131, 875-885 (2006).
34. 1H-NMR spectroscopic metabolioc profiling of urine. Metabolomics 2(1), 1-19 (2006).
35. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC: Scaling and normalization effects in NMR spectroscopic metabonomic data sets Anal. Chem. 78(7) 2262-2267 (2006).
36. Halouska S, Powers R: Negative impact of noise on the principal component analysis of NMR data. J. Magn. Reson. 178(1) 88-95 (2006).
37. Keun HC, Ebbels TMD, Antti H et al.: Improved analysis of multivariate data by variable stability scaling application to NMR-based metabolic profiling. Anal. Chim. Acta 490(1-2) 265-276 (2003).
38. 1H NMR data sets. Anal Chem. 77(5), 1282-1289 (2005).
39. Crockford DJ, Holmes E, Lindon JC et al.: Stistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets application in metabonomic toxicology studies. Anal. Chem. 78(2), 363-371 (2006).
40. Pan Z, Gu H, Talaty N et al.: Principal component analysis of urine metabolites detected by NMR and DESI-MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem. 387, 539-549 (2007).
41. Rantalainen M, Cloarec O, Beckonert O et al.: Statistically integrated metabonomio-proteomic studies on a human prostate cancer xenograft model in mice. J. Proteome Res. 5(10), 2642-2655 (2006).
42. Visapaa H, Bui M, Huang Y et al.: Correlation of Ki-67 ad gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 61(4), 845-850 (2003).
43. Thor AD, Edgerton SM, Liu S, Moore DH, Kwiatkowski DJ: Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers Clin. Cancer Res. 7(8), 2415-2424 (2001).
44. Shieh DB, Godleski J, Hemdon JE et al.: Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma the role of gelsolin expression. Cancer 85(1) 47-67 (1999).
45. Yang J, Tan D, Asch HL et al.: Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer 46(1), 29-42 (2004).
46. Craig A, Sidaway J, Holmes E et al.: Systems toxicology: intagrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J. Proteome Res. 5(7), 1586-1601 (2006).
47. Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19(3), 1720-1730 (1999).
48. 1H NMR-based metabonomic urinalysis. Chem. Res. Toxicol. 15(11), 1380-1386 (2002).
49. Fell D: Understanding the Control of Metabolism. Portland Press Ltd, London, UK (1997).
50. Lindon C, Nicholson JK, Holmes E et al.: Summary recommendations for standardization and reporting of metabolic analyses. Nat. Biotechnol. 23(10), 833-838 (2005).